OrbiMed β 2026 Investments
5 investments dated 2026 Β· listed companies and verified rows first Β· show all
Adela develops blood-based diagnostic tests that analyze cell-free DNA using whole methylome analysis to detect and monitor cancer.
BiotechDigital HealthHealthtechFoster City, US
Daniel Diniz De Carvalho(Executive Officer, Promoter)Scott Bratman(Executive Officer, Director)Anne-Renee Hartman(Founder)Alan Williams(Executive Officer)Lisa Alderson(Executive Officer, Director)Priscilla Huang(Executive Officer)
Board seatDavid BonitaΒ· per SEC Form D
Co-investorsDecheng CapitalF-Prime CapitalDeerfield Management CompanyMenlo Ventures
Thrombolex develops endovascular catheters using pharmaco-mechanical technology to treat arterial and venous thromboembolic (A+VTE) conditions by dissolving blood clots.
BiotechHealthtechMedical DevicesKingston, US
John Cerminaro(Executive Officer)Michael J. Cerminaro(Executive Officer, Director)Marvin Woodall(Executive Officer, Director)Brian G. Firth(Executive Officer, Director)Todd Richmond(Director)Riyaz Bashir(Innovator / Creator of BASHIR Endovascular Catheters)
Board seatDavid BonitaΒ· per SEC Form D
Lycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation.
BiotechHealthtechSouth San Francisco, US
Aetna Wun Trombley(President and CEO)Amy Bachrodt(Chief Financial Officer)Jeremy S. Caldwell(Executive Officer, Director)Chin Lee(Chief Medical Officer)Steve Staben(Chief Scientific Officer)Sofia Touami(Chief Business Officer)
Co-investorsREDMILEVersant VenturesBAM ElevateFranklin TempletonHBM Healthcare InvestmentsInvus+4 more
Pinnacle provides an API for sending RCS, SMS, MMS, and iMessage messages with features like rich cards, carousels, and quick replies.
Developer ToolsE-commerceEnterprise SoftwareMarketing TechSaaSSan Francisco, US
Sean Roades(Founder)inIvan Zhang(Founder)inJustin Zheng(Co-founder)
Co-investorsY Combinator
Terremoto Bio develops next-generation small-molecule therapies using medicinal chemistry, targeting previously "undruggable" disease areas.
BiotechDeep TechSouth San Francisco, US
Grace Lu(Executive Officer)James Christensen(Executive Officer, Director)Charles Baum(Executive Officer, Director)
BoardMichael Goller(Director)Reid Huber(Director)inPeter Thompson(Director)
Co-investorsEcoR1 CapitalRA CapitalNovo HoldingsOsage University PartnersThird Rock Ventures
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.